Prognostic impact of interval breast cancer detection in women with pT1a N0M0 breast cancer with HER2-positive status: Results from a multicentre population-based cancer registry study
Antonino Musolino(Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori), Maria Michiara, Anita Rimanti(Azienda Ospedaliera Carlo Poma), Claudio Zamagni(Policlinico S.Orsola-Malpighi), Angelica Sikokis(University of Parma), R. Degli Esposti(Istituto delle Scienze Neurologiche di Bologna), Giancarlo Bisagni, Fabio Falcini(Centro di Riferimento Oncologico), Laura Cortesi(Azienda Ospedaliero-Universitaria di Modena), Daniela Boggiani(University of Parma), Nicoletta Campanini(University of Parma), Antonio Frassoldati(Italian Oncology Group of Clinical Research), Paolo Sgargi(University of Parma), Luigi Cavanna(University of Pavia), Enrico Maria Silini(Ospedale di Parma), Elena Barbieri(IRCCS Azienda Ospedliero-Universitaria di Bologna Policlinico di Sant'Orsola), Benedetta Pellegrino(University of Parma)
Cited by 3
Related Papers
Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer
|Annals of Oncology|2021|743
Distance as a Barrier to Cancer Diagnosis and Treatment: Review of the Literature
|The Oncologist|2015|531
Sentinel European Node Trial (SENT): 3-year results of sentinel node biopsy in oral cancer
|European Journal of Cancer|2015|386